* *Once completed please combine this form, along with optional max 1XA4 page of figures/data tables, the required CVs, and proof of support (lead organisation, partner organisation and additional stakeholders involved) into a single pdf for submission. It should then be attached to the outline call for “UKRI’s Agile Research and Innovation Response to COVID-19” in Je-S. Detailed instructions on how to submit an application to this call on the Je-S system is available here* [*available here (PDF, 236KB)*](https://www.ukri.org/files/funding/ukris-agile-research-and-innovation-response-to-covid-19-je-s-guidance/)*.* ***Please note only eligible RO’s should submit via Je-S.***

Section 1: Proposal Summary

|  |
| --- |
| 1.1 Title (max. 150 characters) |
|  |

|  |
| --- |
| 1.2 Scientific/technical summary (max. 250 words) |
|       |

|  |
| --- |
| 1.3 Project duration\* |
| Proposed start date (dd/mm/yy) |       |
| Proposed duration of award (months) |    |
| Proposed end date (dd/mm/yy) |       |

\* note max. 18 months. Start date can be from 1 to 3 months from submission

|  |
| --- |
| 1.4 Please provide clear reasons to justify your proposed start date (max 300 words).  |
|       |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1.5 Project cost (£) | FY 20/21 | FY 21/22 | FY22/23 | Total |
|  | *N.B Indicative costs must be within 10% of the final costs submitted* |
| **Indicative costs** |       |       |       |       |

|  |  |
| --- | --- |
| 1.6 Which ONE of the following priority areas does your proposal primarily address? (for full description of these areas, see [here](https://www.ukri.org/files/research-questions-for-covid-19/)).  |  |
| Modelling, AI, digital and data approaches to understanding of the pandemic and mitigating its effects |[ ]
| Engineering and physical sciences approaches for national recovery and transformation |[ ]
| Understanding, monitoring and controlling CV19 transmission |[ ]
| CV19 in the environment |[ ]
| Human-Animal interface |[ ]
| Greening the recovery |[ ]
| Policy and behavioural change |[ ]
| Economic impacts and micro-, macro- and fiscal economic policy |[ ]
| Social impact upon vulnerable groups and regions |[ ]
| Impacts of Covid-19 on cultural and creative sector |[ ]
| Ethical, Regulatory and Human Rights issues in responses to Covid-19 |[ ]
| Communication and Public Health during the pandemic |[ ]
| Mechanistic studies of the disease and its sequela |[ ]
| Epidemiology |[ ]
| Intervention development and early evaluation, including experimental studies |[ ]
| Other (add comment below) |[ ]
|       |  |

Section 2: Principal Investigator Details

|  |
| --- |
| 2.1 Principal Investigator |
| Name |       |
| PI Organisation |       |
| PI Department |       |
| Email address  |       |

Section 3: Importance, Deliverables, Expertise, and Resources

|  |
| --- |
| 3.1 Please describe and justify the importance of the COVID-19 related knowledge gap and/or need that you are targeting (max. 250 words) |
|       |

|  |
| --- |
| 3.2 Please describe how this research adds value to existing Covid19-related activities (max. 250 words). |
|       |

|  |
| --- |
| 3.3 Please describe how the research impact(s) can be scaled to be useful to the UK as a whole (max. 250 words) |
|       |

Section 4: Plan of Research including Importance, Deliverables, and Resources

|  |
| --- |
| 4.1 Please provide an overview of the nature of the proposed research or project (study design, approach and deliverables) (max. 1500 words).  |
|       |

|  |
| --- |
| 4.2 Please define the project’s deliverables and expected outcomes at the 3, 6, 12 and 18 month milestones. This should include an explanation of how deliverables will provide/lead to benefit(s) relating to the health, social, economic, cultural and/or environmental impacts of the COVID-19 outbreak (max 300 words). N.B this information will be made public if the proposal is funded. |
|       |

|  |
| --- |
| 4.3 Please provide a brief description of the resources required in the different contributing environments (staff, materials, data, facilities etc.), including whether these are in hand, or if not, what gives you confidence that they will be accessible when required? (max. 250 words). Note here if you are requesting access to shared UKRI facilities including computational facilities. |
|       |

Section 5: Investigators

|  |
| --- |
| 5.1 Please provide evidence that the team has the necessary expertise, track record and contacts to undertake the proposed work and ensure its impact (max. 250 words). If you are requesting our help in finding support from shared staff pools, note this here.  |
|       |

The following should also be provided. **These should be combined with this form into a single pdf for submission**

**CVs** - Please provide a CV for the PI and Co-Is/Team members. Each CV to provide relevant key publications/outputs and grants and other relevant information indicating their suitability to lead/support the work as described in the application (no more than 1xA4 page per CV using Arial 11 point).

**Institutional approvals** Include evidence of approval from the host institution/company/organisation which confirms you are able to carry out the proposed work under any institutional restrictions currently in place.

An **optional** page of supporting figures, GANTT chart and/or data tables (max 1 page A4)

Annex 1: Regulatory requirements: Please complete as applicable

A. Legislative/Ethical requirements

**Note:** Data produced as a result of this funding must be shared in line with the [Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak](https://wellcome.ac.uk/press-release/sharing-research-data-and-findings-relevant-novel-coronavirus-ncov-outbreak).

|  |
| --- |
| Does this programme involve: |
| **1. Animals?**The use of vertebrate animals or other organisms covered by the Animals (Scientific Procedures) Act 1986[[1]](#footnote-2), whether or not it requires licensed procedures. | Yes/No |
| **1a. Animal Species?**If animals are being used please provide the basic species information e.g. Mouse. |       |
| **2. Human Tissue?**The use of human tissue as defined in the Human Tissue Act 2004[[2]](#footnote-3)? | Yes/No |
| **3. Stem Cells?**Does the research involve the use of Stem Cells or regenerative medicine? | Yes-both/Yes-embryonic/Yes-adult/No |

Note: The MRC will make public information about animal experiments when needed (e.g. as anonymous examples, or in response to direct queries) but will resist all requests for information that might lead to the identification of places or individuals, except with the express permission of the individuals concerned.

B. Additional information for clinical research

|  |
| --- |
| Does this programme involve: |
| **1. Human participation?**Research which requires *face-to-face* contact with *patients*, or with *healthy human participants* (by holders of a clinical contract) and may involve use of patient records as a concomitant, e.g. a clinical trial. | Yes/No |
| **2. Records based studies?**Research which requires *access to personal data* on health or lifestyle *without* involving face-to-face contact with any people, e.g. public health interventions, health economic studies, epidemiological studies, health services research and meta-analyses - information may be obtained by telephone, postal questionnaires/surveys or electronic/manual data retrieval. | Yes/No |
| **3. Clinical samples?**Research which involves *laboratory studies* on *human material* which are specifically designed to understand or treat a disease/disorder. N.B. Basic biomedical research remote from application to a disease/disorder, such as the use of immortalised human cell lines in model biological systems, is excluded. | Yes/No |
| **4. Technology development for clinical use?**Development or adaptation of technologies for diagnosis or therapy, e.g. instrument development for diagnostic or surgical use; development of new techniques, such as photodynamic therapy, for clinical use. | Yes/No |

Note: This information will not be made publicly available in an identifiable format.

C. Additional Analysis Data

|  |
| --- |
| The following data will assist us in scientific and strategic reporting and may be published. |
| **Research Setting**Based on direct patient contact, indicate whether the research involves a particular medical setting such as primary care or secondary care. | None/Other/Emergency/Primary & Secondary/Secondary/Primary |

D. Other ethical considerations

|  |
| --- |
| Other Ethical Considerations |
| Are there other ethical and/or health and safety issues that have been considered | Yes/No |
| **If Yes, please outline (max 100 words)** |
|       |
| Is the ethical approval already in place? | Yes/No |
| Will ethics approval be sought and if so when? | Yes/No      |

1. <http://www.homeoffice.gov.uk/science-research/animal-research/> [↑](#footnote-ref-2)
2. <https://mrc.ukri.org/research/facilities-and-resources-for-researchers/regulatory-support-centre/human-tissue/> [↑](#footnote-ref-3)